GEMFIBROZIL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H22O3
Molecular Weight	250.3334
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1

InChI

InChIKey=HEMJJKBWTPKOJG-UHFFFAOYSA-N

InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C15H22O3
Molecular Weight	250.3334
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01241
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf

Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels (moderately), and increase HDL levels (moderately). Gemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. It does so by activating Peroxisome proliferator-activated receptor-alpha (PPARα) 'transcription factor ligand', a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Gemfibrozil also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. Gemfibrozil is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Solute carrier organic anion transporter family member 1B1 32 Target ID: CHEMBL1697668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16316932	Inhibitor 8504	12.5 µM [Ki]
Cytochrome P450 2C9 50 Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16299161	Inhibitor 8504	30.0 µM [IC50]
Cytochrome P450 2C8 18 Target ID: CHEMBL3721 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176562	Inhibitor 8504	30.4 µM [Ki]
Peroxisome proliferator-activated receptor alpha 62 Target ID: CHEMBL239 Sources: http://www.drugbank.ca/drugs/DB01241	Agonist 2752	59.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperlipidemia 82 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf	Primary		Approved 8583	LOPID Approved Use LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides Launch Date 1981
Coronary heart disease 43 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf	Preventing		Approved 8583	LOPID Approved Use LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides Launch Date 1981

C_max

Value	Dose	Co-administered	Analyte	Population
17400 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01736254	600 mg single, oral dose: 600 mg route of administration: oral experiment type: single co-administered:		GEMFIBROZIL plasma	Homo sapiens population: healthy age: sex: food status:
28 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
104 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520	unhealthy, 59 Health Status: unhealthy Age Group: 59 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7614520	Disc. AE: Depression, Flushing... AEs leading to discontinuation/dose reduction: Depression (1.1%) Flushing (1.1%) Nausea (2.2%) Vomiting (1.1%) Rash (1.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/7614520
9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	healthy, 7 Health Status: healthy Age Group: 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	Disc. AE: Abdominal cramps, Abnormal liver function tests... AEs leading to discontinuation/dose reduction: Abdominal cramps Abnormal liver function tests Diarrhea CPK increased Joint pain Muscle pain Nausea Vomiting Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf

AEs

AE	Significance	Dose	Population
Depression	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520	unhealthy, 59 Health Status: unhealthy Age Group: 59 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7614520
Flushing	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520	unhealthy, 59 Health Status: unhealthy Age Group: 59 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7614520
Rash	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520	unhealthy, 59 Health Status: unhealthy Age Group: 59 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7614520
Vomiting	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520	unhealthy, 59 Health Status: unhealthy Age Group: 59 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7614520
Nausea	2.2% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520	unhealthy, 59 Health Status: unhealthy Age Group: 59 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7614520
Abdominal cramps	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	healthy, 7 Health Status: healthy Age Group: 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf
Abnormal liver function tests	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	healthy, 7 Health Status: healthy Age Group: 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf
CPK increased	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	healthy, 7 Health Status: healthy Age Group: 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf
Diarrhea	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	healthy, 7 Health Status: healthy Age Group: 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf
Joint pain	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	healthy, 7 Health Status: healthy Age Group: 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf
Muscle pain	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	healthy, 7 Health Status: healthy Age Group: 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf
Nausea	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	healthy, 7 Health Status: healthy Age Group: 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf
Vomiting	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	healthy, 7 Health Status: healthy Age Group: 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 1079 OATP2B1 157 OATP1B3 961 OAT3 747 MRP2 499 P-gp 1741 CYP2C8 1057 CYP2C19 2057 CYP1A2 2153 CYP2A6 879 CYP2E1 1060	P-gp 2052 UGT1A1 479 UGT1A3 470 UGT1A4 399 UGT1A6 343 UGT1A7 249 UGT1A8 323 UGT1A9 423 UGT1A10 331 UGT2B4 278 UGT2B7 456 UGT2B15 236 UGT2B17 237

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17523051/\|https://pubmed.ncbi.nlm.nih.gov/16316932/	no
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16316932/\|https://pubmed.ncbi.nlm.nih.gov/14698041/	no
OAT3 749	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/21383204/\|https://pubmed.ncbi.nlm.nih.gov/17455113/	yes [Ki 1.5 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25653502/\|https://pubmed.ncbi.nlm.nih.gov/23139378/\|https://pubmed.ncbi.nlm.nih.gov/17523051/\|https://pubmed.ncbi.nlm.nih.gov/16316932/\|https://pubmed.ncbi.nlm.nih.gov/17470528/	yes [Ki 14.2 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11719730/ \|https://pubmed.ncbi.nlm.nih.gov/11602509/	yes [Ki 5.8 uM]	yes (co-administration study) Comment: [PMID:11719730]:Gemfibrozil modestly increases the plasma concentrations of glimepiride. This may be caused by inhibition of CYP2C9. Sources: https://pubmed.ncbi.nlm.nih.gov/11719730/ \|https://pubmed.ncbi.nlm.nih.gov/11602509/
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	yes
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	yes
OATP1B3 970	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25653502/\|https://pubmed.ncbi.nlm.nih.gov/17470528/	yes
OATP2B1 162	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17470528/	yes
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25941268/\|https://pubmed.ncbi.nlm.nih.gov/22472994/	yes	yes (co-administration study) Comment: [PMID:22472994]: CYP2C8 inactivation by gemfibrozil caused dose-dependent increases in AUC of repaglinide Sources: https://pubmed.ncbi.nlm.nih.gov/25941268/\|https://pubmed.ncbi.nlm.nih.gov/22472994/

Drug as victim

Target	Modality	Activity
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	major
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/14698041/	no
UGT1A10 331	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A7 249	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A8 323	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT2B15 236	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT2B17 237	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5296	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5296
ChemicalBook	CB9154247	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9154247
eMolecules	538915	https://www.emolecules.com/cgi-bin/more?vid=538915
MolPort	MolPort-001-794-413	https://www.molport.com/shop/molecule-link/MolPort-001-794-413
Selleck Chemicals	Gemfibrozil(Lopid)	http://www.selleckchem.com/products/Gemfibrozil(Lopid).html
ZINC	ZINC000001530641	http://zinc15.docking.org/substances/ZINC000001530641

PubMed

Title	Date	PubMed
Therapy and clinical trials.	2002-02	11790971
Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.	2002-01-28	11802751
[Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].	2002-01-25	11795020
Sexual dysfunction secondary to gemfibrozil.	2002-01	11794424
Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial.	2001-12-20	11788126
Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with Vibrio fischeri.	2001-12-14	11771838
[Lipid-lowering drugs].	2001-12	11778457
Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil.	2001-12	11733637
Treatment for the procoagulant state in type 2 diabetes.	2001-12	11727398
Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?	2001-12	11722675
Effects of fenofibrate and gemfibrozil on plasma homocysteine.	2001-11-24	11734263
Effects of fenofibrate and gemfibrozil on plasma homocysteine.	2001-11-24	11734262
Statin-associated myopathy.	2001-11-05	11758079
Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells.	2001-11	11816722
Effect of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara on experimental hypertriglyceridaemia and hypercholesterolaemia induced by Triton WR 1339 (tyloxapol) in mice.	2001-11	11731925
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.	2001-11	11719730
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.	2001-11	11715936
PPARS, metabolic disease and atherosclerosis.	2001-11	11712864
Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?	2001-11	11711005
Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.	2001-11	11701466
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?	2001-11	11694861
Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?	2001-11	11684067
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.	2001-11	11602509
[Cerivastatin and gemfibrozil: a dangerous combination].	2001-10-15	11602128
Cyclic nucleotides in platelets of genetically hypertriglyceridemic and hypertensive rats. Thrombin and nitric oxide responses are unrelated to plasma triglyceride levels.	2001-10-01	11583736
Fatal rhabdomyolysis caused by lipid-lowering therapy.	2001-10	11702815
Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients.	2001-10	11586485
[Fibrates in the secondary prevention of ischemic cardiopathy].	2001-09-22	11565320
[Severe rhabdomyolysis associated with cerivastatin and gemfibrozil].	2001-09-15	11562335
Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats.	2001-09-15	11551527
Bayer pulls cerivastatin (Baycol) from market.	2001-09-04	11563216
Molecular basis for the effect of lipid lowering drugs on growth factors after de-endothelialization.	2001-09	11780395
[Cholestatic hepatitis caused by gemfibrozil].	2001-09	11767440
Cerivastatin and gemfibrozil-associated rhabdomyolysis.	2001-09	11573847
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.	2001-09	11570656
Is the relationship between adipose tissue and waist girth altered by weight loss in obese men?	2001-09	11557833
New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol.	2001-09	11487447
Altered expression of the carboxylesterases ES-4 and ES-10 by peroxisome proliferator chemicals.	2001-08-28	11522369
Baycol withdrawn from market.	2001-08-21	11521677
Bayer decides to withdraw cholesterol lowering drug.	2001-08-18	11509419
Statin-fibrate combination therapy.	2001-08-04	11485144
Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.	2001-08	11764054
[Fatal rhabdomyolysis caused by cerivastatin].	2001-08	11584446
Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine.	2001-08	11483622
Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men.	2001-08	11477498
The effects of lipid-lowering agents on acute renal allograft rejection.	2001-07-27	11477342
Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.	2001-07	11583069
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].	2001-07	11515276
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.	2001	11795072
Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction.	2001	11552053

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose for adults is 1200 mg administered in two divided doses 30 minutes before the morning and evening meals

Route of Administration: Oral

In Vitro Use Guide

Sustained potent reduction of [Ca²⁺]i in cultured rat VSMCs was observed with Gemfibrozil 50mg/L

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:54:17 GMT 2025` Edited by `admin` on `Mon Mar 31 17:54:17 GMT 2025`
Record UNII	Q8X02027X3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GEMFIBROZIL

Official Name

English

LOPID

Preferred Name

English

GEMFIBROZIL [IARC]

Common Name

English

Gemfibrozil [WHO-DD]

Common Name

English

GEMFIBROZIL [HSDB]

Common Name

English

2,2-DIMETHYL-5-(2,5-XYLYLOXY) VALERIC ACID

Systematic Name

English

gemfibrozil [INN]

Common Name

English

GEMFIBROZIL [EP MONOGRAPH]

Common Name

English

GEMFIBROZIL [MART.]

Common Name

English

GEMFIBROZIL [USAN]

Common Name

English

GEMFIBROZIL [USP-RS]

Common Name

English

GEMFIBROZIL [JAN]

Common Name

English

NSC-757024

Code

English

GEMFIBROZIL [ORANGE BOOK]

Common Name

English

GEMFIBROZIL [MI]

Common Name

English

CI-719

Code

English

GEMFIBROZIL [USP MONOGRAPH]

Common Name

English

PENTANOIC ACID, 5-(2,5-DIMETHYLPHENOXY)-2,2-DIMETHYL-

Common Name

English

GEMFIBROZIL [VANDF]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

834821